The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Open accessAbstract
1. Preamble 4361 2. Introduction 4363 3. Estimation of total cardiovascular risk and implications for dyslipidaemia management 4363 4. New low-density lipoprotein cholesterol-lowering therapies 4367 5. Combination of lipid-lowering therapies during index hospitalization for acute coronary syndromes 4369 6. Lipoprotein(a) 4370 7. Hypertriglyceridaemia 4371 8. Primary prevention in people with human immunodeficiency virus infection 4372 9. Patients with cancer at high or very high chemotherapy-related cardiovascular toxicity risk 4373 10. Dietary supplements 4373 11. Evidence tables 4374 12. Data availability statement 4374 13. Author information 4374 14. Appendix 4374 15. References 4375 Recommendation Table 1 — Recommendations for cardiovascular risk estimation in persons without known cardiovascular disease (see also Supplementary data online, Evidence Table 1) 4367 Recommendation Table 2 — Recommendations for pharmacological low-density lipoprotein cholesterol lowering (see also Supplementary data online, Evidence Table 2) 4369 Recommendation Table 3 — Recommendations for lipid-lowering therapy in patients with acute coronary syndromes (see also Supplementary data online, Evidence Table 3) 4370 Recommendation Table 4 — Recommendations for measurement of lipoprotein(a) (see also Supplementary data online, Evidence Table 4) 4370 Recommendation Table 5 — Recommendations for drug treatment of patients with hypertriglyceridaemia (see also Supplementary data online, Evidence Table 5) 4372 Recommendation Table 6 — Recommendations for statin therapy in primary prevention for people with human immunodeficiency virus infection (see also Supplementary data online, Evidence Table 6) 4373 Recommendation Table 7 — Recommendations for statin therapy in patients receiving cancer therapy (see also Supplementary data online, Evidence Table 7) 4373 Recommendation Table 8 — Recommendations for dietary supplements (see also Supplementary data online, Evidence Table 8) 4374 Table 1 Classes of recommendations 4362 Table 2 Levels of evidence 4362 Table 3 Cardiovascular risk categories 4364 Table 4 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels 4365 Figure 1 Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular risk 4366 Figure 2 Average reduction in low-density lipoprotein cholesterol levels with different pharmacological therapies with proven cardiovascular benefits 4368 Figure 3 Association between Lp(a) levels and lifetime risk of major cardiovascular events 4371 Acute coronary syndromes Alanine aminotransferase Apolipoprotein B Apolipoprotein C-III Antiretroviral therapy Atherosclerotic cardiovascular disease Aspartate aminotransferase Aortic valve stenosis Coronary artery calcium Confidence interval Computed tomography Cardiovascular Cardiovascular disease Docosahexaenoic acid European Atherosclerosis Society European Medicines Agency Eicosapentaenoic acid European Society of Cardiology Familial chylomicronaemia syndrome US Food and Drug Administration Familial hypercholesterolaemia High-density lipoprotein cholesterol Human immunodeficiency virus Hazard ratio Low-density lipoprotein cholesterol Lipoprotein(a) Left ventricular ejection fraction Monoclonal antibody Major adverse cardiovascular event(s) Myocardial infarction Percutaneous coronary intervention Proprotein convertase subtilisin/kexin type 9 Peroxisome proliferator-activated receptor n-3 polyunsaturated fatty acid People with HIV Systematic Coronary Risk Evaluation 2 Systematic Coronary Risk Evaluation 2-Older Persons Total cholesterol Type 1 diabetes mellitus Type 2 diabetes mellitus Upper limit of normal Guidelines evaluate and summarize available evidence with the aim of assisting health professionals in proposing the best diagnostic or therapeutic approach for an individual patient with a given condition. The European Society of Cardiology (ESC) Guidelines are intended for use by health professionals but do not override their individual responsibility to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with the patient or the patient's caregiver where appropriate and/or necessary aiming at shared care decisions. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription and to respect the ethical rules of their profession. The ESC Guidelines represent the official position of the ESC on a given topic. Guideline topics are selected for updating after annual expert review of new evidence conducted by the ESC Clinical Practice Guidelines (CPG) Committee. ESC Policies and Procedures for formulating and issuing the ESC Guidelines can be found on the ESC website (https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines). Interim
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Importantly, the guidelines highlight that variability in LDL-C lowering is observed across all treatment options, likely reflecting differences in background LLT regimens [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In line with this, they emphasize the importance of monitoring LDL-C response 4 to 6 weeks after initiation or intensification and making timely treatment adjustments to achieve recommended targets [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent ESC/EAS 2025 Focused Update Guideline [9] emphasizes that elevated TG and TRLs contribute independently to cardiovascular risk, even in patients achieving LDL-C targets.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The recent 2025 ESC/EAS Focused Update confirms this guidance, emphasizing the persistent role of statins as the cornerstone therapy for cardiovascular risk reduction in the presence of elevated TG, not only by targeting LDL-C but also by modulating TRLs and reducing the atherogenic potential of the lipid profile [9].”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The recommendations position bempedoic acid alongside other established LLTs with demonstrated cardiovascular-risk reduction such as statins, ezetimibe, and PCSK9i.”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Guidelines also recommend that the choice of treatment should not only be made based on the magnitude of additional LDL-C lowering needed, but also patient preference, treatment availability, and cost [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“The 2025 ESC/EAS guidelines for the management of dyslipidemia provide new recommendations for bempedoic acid in both patients unable to take statins and as an adjunct to maximally tolerated statin therapy, with or without ezetimibe, including use in high- and very high-risk patients [45].”
From Systematic literature review on the real-world effectiveness and safety of bempedoic acid (2026) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“the 2025 ESC/EAS Focused Update [9] emphasizes that consistent cardiovascular benefit has not been demonstrated in the overall population, and fibrate therapy should therefore be reserved for carefully selected patients with persistent hypertriglyceridaemia or features of atherogenic dyslipidemia despite optimal LDL-C lowering”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
The cited source says what the claim attributes to it.
In the citing paper
“Overall, the joint guideline recognizes TG/TRL-mediated risk as a modifiable component of residual cardiovascular risk, addressed pragmatically through non–HDL-C/apoB targets and selective TG-lowering therapies integrated with intensive LDL-C reduction, with non-fasting testing as the default approach.”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [9]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Self-citationCholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citation2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad191 · Cited by 5,333
Self-citationEzetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962
Self-citation2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C. J., Andreotti, F., Koskinas, K. C., Rosselló, X., Adamo, M., Ainslie, J., BANNING, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 3,521
Self-citationLyon, A. R., López‐Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J. K., Boriani, G., Cardinale, D. M., Córdoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,457
Self-citationCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Cited by
Sorted by citations
Items 301–400 of 817
Dyslipidemia Patterns in Adults with Congenital Heart Disease: Focus on HDL Cholesterol
Martínez‐Quintana, E., & Rodríguez‐González, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14238357
Catapano, A. L., Maggioni, A. P., Rossi, F., Consolo, E., Notarianni, L., & Agnelli, G. (2025) · International Journal of Cardiology Cardiovascular Risk and Prevention · doi:10.1016/j.ijcrp.2025.200549
Self-citationScicchitano, P. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.12.001
Kokina, B., Lapsovs, M., Roze, R., Lāce, B., Ērglis, A., & Trušinskis, K. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1622667
Rubboli, A., & Atar, D. (2025) · Cardiology · doi:10.1159/000549952
Lp(a) and cardiovascular risk: insights from a young multiethnic cohort in Dubai
Musumeci, G., & Quadri, G. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.134085
Kudaiberdieva, G. (2025) · Heart Vessels and Transplantation · doi:10.24969/hvt.2025.615
Andrade, V. C., Rezende, P. C., Hueb, W. A., Garcia, R. M. R., de Assis, A. C. R., da Silva, M. F., Ribeiro, M. D. O. L., Mocha, M. R., Tairova, M. S., Ramires, J. A. F., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02027-6
Prognostic value of lipoprotein(a) in a primary prevention ambulatory cohort
Golan, N., Freund, O., Itach, T., & Arbel, Y. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02826-x
Insights into the 2025 ESC focused update on the management of dyslipidemias
SEC Working Group for the 2025 ESC focused update on the management of dyslipidemias and SEC Guidelines Committee (2025) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2025.12.009
Alawainati, M., AlGhareeb, N., Najem, W., AlGhareeb, M., Alhouli, R., Alqallaf, A., Buhejji, M., Almulla, A., Obaid, S., AlRabiah, J., et al. (2025) · Cureus · doi:10.7759/cureus.99184
Salib, A., Kataoka, Y., Nicholls, S. J., Kitahara, S., Funabashi, S., Makino, H., Matsubara, M., Matsuo, M., Omura‐Ohata, Y., Koezuka, R., et al. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.011
Formisano, E., Pasta, A., & Pisciotta, L. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.12.014
Hưng, C. Đ., Tri, B. M., Lộc, T. P., Thảo, N. T. T., Ry, M., & Minh, N. Q. (2025) · Tạp chí Nghiên cứu Y học · doi:10.52852/tcncyh.v197i12.4261
IMPORTANCE OF EARLY DIAGNOSIS AND MANAGEMENT OF DYSLIPIDEMIA IN CARDIOVASCULAR DISEASE PREVENTION
Bluszcz, M., Muszkiet, Z., Roczniak, P., Bar, M., Truchel, D., Rysak, A., Krzywda, A., Poszwa, D., Dynowska, Z., & Rajczyk, K. (2025) · Archiv Euromedica · doi:10.35630/2025/15/iss.6.601
In what ways can we elevate action around Lp(a) as new risk factor for Cardiovascular Disease?
Rodenbach, A., Rietzschel, E. R., Bertels, J., Bondue, A., Daubie, M., Demyttenaere, B., Jaeger, P. D., Depoorter, K., Rocker, H. D., Gruson, D., et al. (2025) · Ghent University Academic Bibliography (Ghent University)
Self-citationGuijarro, C., & Ortiz, A. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120633
Gu, T., Liu, J., Qi, Z., Zhang, Y., Hu, S., Zhang, Z., Xue, Z., Liu, T., & Chen, K. Y. (2026) · Lipids in Health and Disease · doi:10.1186/s12944-025-02844-8
Wieczorek, E., Feliksiak, M., Kuchta, A., Jankowski, M., & Ćwiklińska, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27020556
When “more statin” adds little: Rethinking intensification in the era of early combination therapy
Giallauria, F., Vallefuoco, G., & Cuomo, G. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134166
Hu, Z., Dong, H., & Huang, X. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1763899
Ergül, E., Durak, H., Çetın, M., DUMAN, H., Emlek, N., Yilmaz, A. S., Özyıldız, A., Barutçu, G., & Cüre, O. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020595
Gallo, G., & Volpe, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf1071
Li, Z., Guan, X.-C., Li, X., Chen, Y.-Y., Ruan, F., & Long, L. (2026) · BMC Cardiovascular Disorders · doi:10.1186/s12872-026-05518-0
Reflexiones sobre la actualización ESC 2025 sobre el tratamiento de las dislipemias
Olmo, R. F. (2026) · Revista Española de Cardiología · doi:10.1016/j.recesp.2025.11.022
Reassessing the First Step: Lessons From ES-BempedACS and the Era of Multi-Mechanism LDL-C Lowering
Grant, J. K., & Leucker, T. M. (2026) · Circulation · doi:10.1161/circulationaha.125.077771
Apolipoprotein B for the refinement of cardiovascular risk assessment
Katzmann, J. L., & Laufs, U. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag047
Self-citationBonanni, L. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106710
蒋, 鹏. (2026) · Advances in Clinical Medicine · doi:10.12677/acm.2026.161273
Тимощенко, О. В., Шахтшнейдер, Е. В., Иванощук, Д. Е., Zorina, V., Orlov, P., Semaev, S., & Ragino, Y. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031214
Lanthier, L., Mutchmore, A., Plourde, M.-É., & Cauchon, M. (2026) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2026.01.002
Achenbach, S. S., Smetak, N., Assmann, A., Dörge, H., Thiele, H., Gummert, J. F., Hell, M. M., Rudolph, T. K., Doenst, T., Falk, V., et al. (2026) · Die Kardiologie · doi:10.1007/s12181-025-00785-1
ESC-Leitlinien 2025 – neue und revidierte Empfehlungen
Dörr, R., & Maisch, B. (2026) · Herz · doi:10.1007/s00059-025-05356-4
Achenbach, S. S., Smetak, N., Assmann, A., Dörge, H., Thiele, H., Gummert, J. F., Hell, M. M., Rudolph, T. K., Doenst, T., Falk, V., et al. (2026) · Zeitschrift für Herz- Thorax- und Gefäßchirurgie · doi:10.1007/s00398-026-00761-1
Nardi, F., Patti, G., QUADRI, G., Pollarolo, L., Alunni, G., Andriani, M., Angelini, A., Bertolazzi, M., Boccuzzi, G. G., Capriolo, M., et al. (2026) · Giornale italiano di cardiologia · doi:10.1714/4636.46470
Kliś, K. M., Łasocha, B., Szydłowski, I., Gąsowski, J., Pomierny, B., Cierniak, A., Kwinta, B. M., Stachura, K., & Krzyżewski, R. M. (2026) · Neurosurgical Review · doi:10.1007/s10143-025-04117-5
Saberi‐Karimian, M., Mohammadi‐Bajgiran, M., Shabani, N., Farsi, F., Soflaei, S. S., Farrokhzadeh, F., Moghadam, H. K., Esmaily, H., Moohebati, M., Ferns, G. A., et al. (2025) · Archives of Iranian Medicine · doi:10.34172/aim.34909
Skowron, K. P., Dziewierz, A., Rewiuk, K., Pałka, M., Bobrowska, B., Bartuś, S., Grodzicki, T. K., & Rajtar-Salwa, R. (2026) · Kardiologia Polska · doi:10.33963/v.phj.111059
Vinhas, A. I. D. M. R. (2025) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)
Guo, Y., Ye, F., Ban, M., Yuan, H., & Huang, Q. (2026) · Preprints.org · doi:10.20944/preprints202602.0478.v1
Closing the LDL-C gap: Lessons from the Portuguese SANTORINI subanalysis
Fontes‐Carvalho, R. (2026) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2026.01.003
New insights into the treatment of hyperlipidemia: An expert review
Tomlinson, B. (2026) · 童綜合醫學雜誌 · doi:10.4103/etmj.etmj-d-25-00051
Hosseini, F., Labinaz, A., Lee, T., Brunham, L. R., Mancini, G. B. J., Singer, J., Turgeon, R. D., Wong, G. C., & Fordyce, C. B. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag117
Inconsistent risk stratification thresholds across European guidelines: A call for harmonization
Santos, J. F., Ladeiras‐Lopes, R., & Dores, H. (2026) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.12.006
Alhabib, R. K., Kholaif, N., Mahmoud, M., Alnwiji, A., Zubair, F. A., Almir, H. H. A., Alzoman, A. S., Alqahtani, A. A., Alsharkawy, R., Albahar, Z. M., et al. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13020100
Schirmer, B., & Schuler, J. C. (2026) · Springer eBooks · doi:10.1007/978-3-662-72738-6_11
Kumar, S., Shyam-Sundar, V., Archbold, A., Ferket, B. S., Ricci, F., & Khanji, M. Y. (2026) · European Heart Journal - Imaging Methods and Practice · doi:10.1093/ehjimp/qyag034
Jeedigunta, M., Reddy, V. V., & Paramasivam, G. (2026) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2025.104163
Another brick in the wall of severe hypertriglyceridaemia lowering
Pedicino, D., & Vergallo, R. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag124
Santas, E., Núñez, E., Borja, E. R., Giráldez, A. P., Murria, R., Vergara, C., Merenciano-Gonzalez, H., Sanchís, J., Nunez, J., & de la Espriella, R. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101513
Vanhulle, A., Yurdaer, D., Calster, L. V., Willems, A., Moerman, V., & Sutter, J. D. (2026) · Acta Clinica Belgica · doi:10.1080/17843286.2026.2638804
The 2025 AACE Dyslipidemia Guidelines – Cost concerns over evidence and missing the target?
Subramanian, S., Kalra, D. K., & Wong, N. D. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.10.071
Polypharmazie in der Gefäßchirurgie
Morath, B., Chiriac, U., & Meisenbacher, K. (2026) · Gefässchirurgie · doi:10.1007/s00772-026-01319-z
Familial hypercholesterolemia presenting as triple-vessel coronary artery disease in a young male
Khan, H., & Khurshid, A. (2026) · Next research. · doi:10.1016/j.nexres.2026.101578
Park, E. J., Park, Y., Kang, D. O., Park, S., Roh, S., Na, J. O., Kim, J. W., Kim, E. J., Rha, S., Park, C. G., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1722107
PCSK9 inhibitors conquer primary prevention: the VESALIUS-CV study
Gatto, L., Bitonto, M. P. D., Scalia, L., Biccirè, F. G., & Prati, F. (2026) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suag032
Could Malnutrition Be a Potential Parameter for Cardiac Risk Assessment in Older Adults?
Özgün, Ö., Baş, A. O., Cengiz, D., Kayabaşı, C., Uyar, A., Turhan, O., Nacar, İ. A., Çıkın, C., Pehlivan, M., Balcı, C., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15062135
Schmid, E. C. (2026) · Heilpflanzen · doi:10.1055/a-2728-0588
Cherska, M., Pavlenko, O., Zlatkina, V. V., Kuts, L., Taraniuk, K., Деміхов, О., Storozhenko, T. Y., Koleva-Tyutyundzhieva, D. I., Kukharchuk, K., Gohary, A. E., et al. (2026) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(89).2026.07
Zlatkina, V. V., Nesen, А. О., & Demikhova, N. V. (2026) · Ukrainian Journal of Nephrology and Dialysis · doi:10.31450/ukrjnd.1(89).2026.10
Dholariya, S. J., Singh, R., Joshi, K., Parchwani, D. N., Anandani, G., & Sonagra, A. D. (2026) · Postgraduate Medicine · doi:10.1080/00325481.2026.2639104
Steen, D. L., Ray, K. K., Khan, I., Catapano, A. L., Bhatt, D. L., Koumas, A., Pol, K., & Giugliano, R. P. (2026) · Journal of clinical lipidology · doi:10.1016/j.jacl.2026.03.007
Self-citationCardio-renal-metabolic syndrome and its management in clinical practice
Šatný, M. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.091
Pilot study evaluating a clinical decision support tool: “Virtual Lipidologist HTE-DLP 3.0”
Zamora, A., Soler, C., Ortega, E., Martín-Urda, A. I., Mora, J., Rivas, M. C. A., Sevilla, J. C., Vila, À., Ibarrexte, D., Pérez-Bernalte, R. M., et al. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500893
Mahajan, K., Jena, S., Dutta, D., Kamrul-Hasan, A. B. M., Sharma, J. B., Himral, S., Mansk, P. G., & Mahajan, N. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70663
HIV Exacerbates Atherosclerosis by Altering Macrophage Function
Lozano-Gerona, J., Yap, J., Vanapruks, S., Irei, J. S., Bishop, T., & Boisvert, W. A. (2026) · CardioMetabolic Syndrome Journal · doi:10.51789/cmsj.2026.6.e18
Tokhi, M., & Siddiqui, A. (2026) · InnovAiT Education and inspiration for general practice · doi:10.1177/17557380261429069
Al-Hetar, M. A. M. Y., Wahab, N. A., Al-Shawky, S., Al-Matary, A. M., Senan, D. A. M., Alezzy, M. E., AlHetar, M. M., & Asaber, A. M. (2026) · Cureus · doi:10.7759/cureus.105450
Guideline inertia and patient non-adherence in secondary prevention: two sides of the same coin
Kunz, M., Leibundgut, G., & Mahfoud, F. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag047
Self-citationNardin, S., Vezzoli, F., Cognolato, G., Mollace, R., Pollone, B. R., Biello, F., Cao, D., Tagliamento, M., Sarocchi, M., Pagnesi, M., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1790897
Koutsogianni, A. D., Barkas, F., Tellis, C. C., Tselepis, A. D., Liamis, G. L., Tsimikas, S., & Liberopoulos, E. N. (2026) · Clinical Research in Cardiology · doi:10.1007/s00392-026-02896-5
Balasooriya, C. M., Jennings, C. S., Kenny, E., Bacquer, D. D., Ray, K. K., Corry, J.-P., Adamska, A., Kotseva, K., McEvoy, J. W., Noone, C., et al. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101576
Is there a role for measuring coronary artery calcium progression in 2026?
Dzaye, O. D. A., Blaha, M. J., & Razavi, A. C. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101557
Martynenko, A., Ilnitski, A. N., Voronina, E. A., & Kashtalap, V. V. (2025) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2025-14-6-105-117
Nam, D., Seo, J., Jang, M., Thakur, S., Nusinovici, S., Park, T. H., Yoo, T. K., Rim, T. H., Bakhai, A., Papadopoulou, S., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8774970/v1
Mancini, G. B. J. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag159
Benabdellah, M., Mesfioui, M. B., Ouartassi, H. E., Boussaadani, B. E., & Raissuni, Z. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag227
Redefining cardiovascular risk: Moving toward an integrated assessment of coronary inflammation
Russo, M., Montone, R. A., & Zimarino, M. (2026) · International Journal of Cardiology · doi:10.1016/j.ijcard.2026.134454
Giannakopoulou, S. (2026) · International Journal of Clinical and Translational Medicine · doi:10.53941/ijctm.2026.100006
From child to family: rethinking cascade screening for elevated Lipoprotein(a)
Pirillo, A., & Catapano, A. L. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag174
Self-citationHigh lipoprotein(a)—a lifelong risk factor and mortality predictor
Kamstrup, P. R. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag188
Unravelling the bidirectional relationship between breast cancer and cardiovascular disease
Abou‐Raya, A., & Abou-Raya, S. (2026) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2026.120728
Lionis, C. D., Kosti, R. I., Yannakoulia, M., Derdemezis, C. S., & Damigou, E. (2025) · Journal of Atherosclerosis Prevention and Treatment · doi:10.4103/aptj.aptj_24_26
Dogan, O., Barman, H. A., Ebeoğlu, A. Ö., Ebeoğlu, Ş. İ., Nayir, A., Kaya, M., Atıcı, A., MIRZAYEV, K., Abacı, O., Ersanli, M. K., et al. (2026) · Angiology · doi:10.1177/00033197261435380
PCSK9 inhibitors in the prevention of vascular events - a review of current evidence
Rucki, M., Cieleban, N., Rucka, A. M., Modliborska, M., & Kowalski, M. (2026) · Journal of Education Health and Sport · doi:10.12775/jehs.2026.89.70057
Lipids and Cardiovascular Diseases: Epidemiologic Perspectives
Nguyen, X.-M. T., Wilson, P. W. F., Okamura, T., Sugiyama, D., Hirata, T., Kuwabara, K., & Hirata, A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-15734-9.00066-2
Vascular age: a tool to facilitate communication with patients about cardiovascular risk
Brotons, C., & Moral, I. (2026) · Clínica e Investigación en Arteriosclerosis (English Edition) · doi:10.1016/j.artere.2026.500936
Ruscica, M., Tassistro, E., Rizzuto, A. S., Macchi, C., Orlando, A., Rebora, P., Carugo, S., Parati, G., Giussani, M., Corsini, A., et al. (2026) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2026.104754
Bartošková, K., & Motovska, Z. J. (2026) · Vnitřní lékařství · doi:10.36290/vnl.2026.018
Lp(a): A potentially modifiable cardiovascular risk factor
Hilleman, D. E., & Backes, J. M. (2026) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxag110
Kuryata, O. V., & Sirenko, O. Y. (2026) · Medicni perspektivi · doi:10.26641/2307-0404.2026.1.356898
Lipoprotein(a): Role in Cardiovascular Risk and Advances in Novel Therapeutics
Sotela, A. M., Loaiza, G. O., Villalobos, P. V., & Guerra, J. A. (2026) · Cureus · doi:10.7759/cureus.106817
Brotons, C., & Moral, I. (2026) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/j.arteri.2026.500936
Li, S., Hu, X., & Li, T. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag213
Raspail, L., Taylor, S., van Lennep, J. E. R., Gonzalez-Juanatey, J. R., Ray, K. K., & Santos, R. D. (2026) · Global Heart · doi:10.5334/gh.1548
Brandenburg, V. (2026) · Nephrologie aktuell · doi:10.1055/a-2748-5190
Современные стратегии профилактики ишемической болезни сердца у пациентов с сахарным диабетом 2 типа
Азаматжонов, А., Ганиев, С., Хусанов, Р., Эргашбоев, Д., & Матюсупов, Х. (2026) · Eurasian Journal of Medical and Natural Sciences · doi:10.70413/ejmns-v06-i04-s48820
Filho, D. A. A., Cesena, F. Y., Miname, M. H., Takematsu, H., Santos, I. S. S., Benseñor, I. M., Lotufo, P. A. L., & Santos, R. D. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101646
Metadata
- Authors
- Mach, F., Koskinas, K. C., Roeters van Lennep, J. E., Tokgözoğlu, L., Badimon, L., Baigent, C., Benn, M., Binder, C. J., Catapano, A. L., De Backer, G. G., Delgado, V., Fabin, N., Ference, B. A., Graham, I. M., Landmesser, U., Laufs, U., Mihaylova, B., Nordestgaard, B. G., Richter, D. J., Sabatine, M. S., ESC/EAS Scientific Document Group, Mueller, C. E., Drexel, H., Abreu, A., Adamo, M., Aktaa, S., Asselbergs, F. W., Baldini, A., Boriani, G., Brida, M., Brodmann, M., Cenko, E., Dagres, N., Dopheide, J., Ebenbichler, C., Gandjbakhch, E., Gorog, D. A., Gouni-Berthold, I., Guasti, L., Heidecker, B., Ibanez, B., James, S., Juni, P., Kałużna-Oleksy, M., Krychtiuk, K. A., Lip, G. Y. H., Lorusso, R., Mahfoud, F., Metra, M., Moelgaard, I., Morais, J., Neubeck, L., Nissen, S. E., Osto, E., Parhofer, K. G., De Isla, L. P., Pesce, M., Petrulioniene, Z., Prescott, E., Rietzschel, E., Rocca, B., Rodriguez Palomares, J. F., Rossello, X., Sannino, A., Semb, A. G., Siller-Matula, J. M., Socrates, T., Tanner, F. C., Wojta, J., Zambon, A., Zeppenfeld, K., Laredj, N., Hayrapetyan, H., Speidl, W. S., Samadov, F., van de Borne, P., Kusljugic, Z., Postadzhiyan, A., Heracleous, H., Ostadal, P., Henriksen, F. L., Mohamed, M. S., Viigimaa, M., Juonala, M., Boccara, F., Chukhrukidze, A., Weingärtner, O., Marketou, M., Kiss, R. G., Sigurdsson, A. F., Maher, V., Henkin, Y., Nodari, S., Bekbossynova, M., Ibrahimi, P., Mirrakhimov, E., Jegere, S., Arnaout, S., Bheleel, O., Plisiene, J., Visser, L., Abela, M., Ivanov, V., Boskovic, A., Mbarek, N., Leening, M. J. G., Bosevski, M., Vesterbekkmo, E. K., Kubica, J., Ferreira, J., Pop, D., Stefanelli, U. M., Giga, V., Pella, D., Fras, Z., Fernandez-Olmo, R., Nilsson, L., Sudano, I., Marjeh, M. Y. B., Triki, F., Degertekin, M. M., Mitchenko, O., Banerjee, A., & Shek, A.
- Affiliations
- (Switzerland)
- (Netherlands)
- (Türkiye)
- (Spain)
- (United Kingdom)
- (Denmark)
- (Austria)
- (Italy)
- (Belgium)
- (Ireland)
- (Germany)
- (Greece)
- (United States of America)
- (Portugal)
- (Croatia)
- (France)
- (Sweden)
- (Poland)
- (Austria/Switzerland)
- (Italy/Saudi Arabia)
- (Lithuania)
- (Norway)
- Corresponding author
- Mach, François
- Koskinas, Konstantinos C
- ORCID
- Mach, François
- Koskinas, Konstantinos C
- Roeters van Lennep, Jeanine E
- Tokgözoğlu, Lale
- Badimon, Lina
- Baigent, Colin
- Benn, Marianne
- Binder, Christoph J
- Catapano, Alberico L
- De Backer, Guy G
- Delgado, Victoria
- Fabin, Natalia
- Graham, Ian M
- Landmesser, Ulf
- Laufs, Ulrich
- Mihaylova, Borislava
- Nordestgaard, Børge Grønne
- Richter, Dimitrios J
- Sabatine, Marc S
- Mueller, Christian Eugen
- Drexel, Heinz
- Abreu, Ana
- Adamo, Marianna
- Aktaa, Suleman
- Asselbergs, Folkert W
- Boriani, Giuseppe
- Brida, Margarita
- Brodmann, Marianne
- Cenko, Edina
- Dagres, Nikolaos
- Dopheide, Jörn
- Ebenbichler, Christoph
- Gandjbakhch, Estelle
- Gorog, Diana A
- Guasti, Luigina
- Heidecker, Bettina
- James, Stefan
- Krychtiuk, Konstantin A
- Lip, Gregory Y H
- Lorusso, Roberto
- Mahfoud, Felix
- Metra, Marco
- Neubeck, Lis
- Nissen, Steven E
- Osto, Elena
- Parhofer, Klaus G
- Pesce, Maurizio
- Prescott, Eva
- Rietzschel, Ernst
- Rocca, Bianca
- Sannino, Anna
- Semb, Anne Grete
- Siller-Matula, Jolanta M
- Socrates, Thenral
- Tanner, Felix C
- Wojta, Johann
- Zambon, Alberto
- Zeppenfeld, Katja
- Hayrapetyan, Hamlet
- Speidl, Walter Stefan
- Samadov, Fuad
- van de Borne, Philippe
- Postadzhiyan, Arman
- Henriksen, Finn Lund
- Juonala, Markus
- Boccara, Franck
- Chukhrukidze, Archil
- Weingärtner, Oliver
- Marketou, Maria
- Nodari, Savina
- Bekbossynova, Makhabbat
- Mirrakhimov, Erkin
- Bheleel, Osama
- Abela, Mark
- Ivanov, Victoria
- Leening, Maarten J G
- Bosevski, Marijan
- Vesterbekkmo, Elisabeth K
- Kubica, Jacek
- Ferreira, Jorge
- Pop, Dana
- Giga, Vojislav
- Pella, Daniel
- Sudano, Isabella
- Triki, Faten
- Mitchenko, Olena
- Banerjee, Amitava
- Shek, Aleksandr
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2025-08-29
- Volume
- 46
- Issue
- 42
- Pages
- 4359-4378
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W4413804012
- Cited by
- 688
- References
- 136
- Citations by year
- 2026: 601 · 2025: 87
- FWCI
- 649.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Heart Journal (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- IrInSubria (University of Insubria) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
- Keywords
- dyslipidemia, dyslipidemia management, cardiovascular risk prediction, LDL-C lowering therapy, acute coronary syndrome, lipoprotein(a), hypertriglyceridemia, HIV infection, cancer patients, statins, dietary supplements, treatment goals, cardiovascular risk reduction, cardiovascular mortality, cardiovascular hospitalization, cardiovascular disease prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
